PLD Clinical Trials

4 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Doxil®, Pegylated Liposomal Doxorubicin, Pegylated liposomal doxorubicin

Pipeline

Phase 1: 1Phase 2: 2Phase 2/3: 1

Top Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1
Regeneron Pharmaceuticals1
Daiichi Sankyo1
Ascentage Pharma Group Inc.1

Indications

Cancer4
Platinum-resistant Recurrent Ovarian Cancer1
Solid Cancer1
Fallopian Tube Cancer1
Primary Peritoneal Cancer1

Other2 trials

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Phase 1

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Phase 2

Birmingham, Alabama1 trial

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2

Anchorage, Alaska1 trial

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Alaska Women's Cancer Care

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.